Novo Nordisk looks into starting GLP-1 drug trials for addiction
Novo Nordisk Exploring GLP-1 Drugs for Addiction Treatment
Novo Nordisk is considering investigating its GLP-1 therapies for treating addictions6
This mirrors similar comments made by rival company Eli Lilly6
Novo is already studying semaglutide in a Phase 2 trial for alcoholic liver disease6
### Background on GLP-1 Drugs and Addiction:
GLP-1 receptor agonists like Ozempic and Wegovy are currently used for diabetes and weight loss45
There's growing interest in their potential to treat substance use disorders345
Preclinical studies show GLP-1 drugs may reduce rewarding properties of addictive substances8
Promising Early Re
Sources:
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8820218/
4. https://news.luc.edu/stories/research/researchers-find-potential-in-diabetes-drugs-for-treating-addiction/
5. https://www.pbs.org/newshour/health/study-suggests-obesity-drugs-could-help-with-alcohol-cravings
6. https://endpts.com/novo-nordisk-looks-into-starting-glp-1-drug-trials-for-addiction/
8. https://news.unchealthcare.org/2023/12/use-of-glp-1-receptor-agonists-to-treat-substance-and-alcohol-use-disorders-is-promising-but-premature/